{"result": "{\n    \"title\": \"Drotrecogin Alfa (Activated) and Septic Shock Therapies\",\n    \"summary\": \"This report explores the interconnected entities involved in the development, evaluation, and market withdrawal of Drotrecogin Alfa (Activated), a medication for septic shock, and the subsequent research into alternative therapies such as Hydrocortisone-Plus-Fludrocortisone. It highlights the roles of Eli Lilly, the APROCCHSS trial, and the French Ministry of Social Affairs and Health in the context of septic shock treatment research.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical nature of septic shock treatment and the significant implications of withdrawing a once-promising medication from the market.\",\n    \"findings\": [\n        {\n            \"summary\": \"Withdrawal of Drotrecogin Alfa (Activated) from the market\",\n            \"explanation\": \"Drotrecogin Alfa (Activated), also known as Xigris, was a significant treatment for septic shock due to its antithrombotic, antiinflammatory, and profibrinolytic properties. Despite initial use, it was withdrawn in 2011 after further trials failed to confirm a survival benefit. This withdrawal marked a pivotal moment in the treatment of septic shock, highlighting the challenges in developing effective therapies for this condition. [Data: Entities (168, 372); Relationships (76, 300, 413)]\"\n        },\n        {\n            \"summary\": \"Impact of the APROCCHSS trial on septic shock treatment research\",\n            \"explanation\": \"The APROCCHSS trial, funded by the French Ministry of Social Affairs and Health and the Programme Hospitalier de Recherche Clinique 2007, played a crucial role in evaluating the effectiveness of Hydrocortisone-Plus-Fludrocortisone therapy in septic shock patients. This trial's findings, showing a reduction in 90-day all-cause mortality compared to placebo, have contributed to the ongoing search for viable treatments for septic shock, underscoring the importance of continuous research and evaluation. [Data: Entities (370, 371, 373); Relationships (564, 565, 563)]\"\n        },\n        {\n            \"summary\": \"Role of Eli Lilly in the development and withdrawal of Drotrecogin Alfa (Activated)\",\n            \"explanation\": \"Eli Lilly, as the producer of Drotrecogin Alfa (Activated), played a significant role in its development and subsequent market withdrawal. This decision reflects the complexities and responsibilities pharmaceutical companies face in ensuring the safety and efficacy of their products. The withdrawal of Xigris from the market underscores the importance of rigorous clinical trials and post-marketing surveillance in the pharmaceutical industry. [Data: Entities (168); Relationships (10, 413)]\"\n        },\n        {\n            \"summary\": \"The potential interaction between Drotrecogin Alfa (Activated) and Hydrocortisone-Plus-Fludrocortisone\",\n            \"explanation\": \"The potential interaction between Drotrecogin Alfa (Activated) and Hydrocortisone-Plus-Fludrocortisone was not assessed due to the withdrawal of Xigris from the market. This gap in research highlights the challenges in understanding the complex interactions between different therapies for septic shock and the need for comprehensive studies to evaluate combined treatment effects. [Data: Relationships (415)]\"\n        },\n        {\n            \"summary\": \"Continued research and development efforts in septic shock treatment\",\n            \"explanation\": \"The withdrawal of Drotrecogin Alfa (Activated) and the outcomes of the APROCCHSS trial underscore the ongoing need for research and development in the field of septic shock treatment. These events highlight the critical importance of finding effective therapies for septic shock, a condition with high mortality rates. The involvement of various entities, including pharmaceutical companies, clinical trials, and funding bodies, illustrates the collaborative effort required to advance medical treatment and improve patient outcomes. [Data: Entities (168, 369, 370); Relationships (76, 75, 563)]\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n168,DROTRECOGIN ALFA (ACTIVATED),\"Drotrecogin alfa (activated) was a medication with antithrombotic, antiinflammatory, and profibrinolytic properties, initially used in the treatment of severe sepsis and septic shock. It is a recombinant human activated protein C. Despite its early use, Drotrecogin alfa (activated) was withdrawn from the market in 2011 due to subsequent trials that did not confirm its survival benefit for patients. This decision followed its examination in various studies, including the APROCCHSS trial, which tested its effectiveness in patients with septic shock, particularly in combination with corticosteroids. However, its relevance and use in clinical practice diminished following its market withdrawal, marking the end of its consideration as a therapeutic option for septic shock.\",7\n369,HYDROCORTISONE-PLUS-FLUDROCORTISONE,\"A therapy evaluated in a clinical trial for its effectiveness in treating septic shock, showing a reduction in 90-day all-cause mortality compared to placebo\",2\n370,APROCCHSS,The clinical trial named Activated Protein C and Corticosteroids for Human Septic Shock that evaluated the effect of hydrocortisone-plus-fludrocortisone therapy on septic shock patients,4\n372,XIGRIS,\"Xigris, the brand name for drotrecogin alfa (activated), was a drug used in the treatment of septic shock. It was the commercial form of drotrecogin alfa (activated) available on the market. However, Xigris was withdrawn from the market in October 2011. This withdrawal was due to concerns over its efficacy and safety, leading to its discontinuation. The decision to withdraw Xigris was consistent across all descriptions, highlighting its removal from the market in 2011 after being identified as a treatment option for septic shock.\",2\n371,FRENCH MINISTRY OF SOCIAL AFFAIRS AND HEALTH,The funding body for the APROCCHSS clinical trial through Programme Hospitalier de Recherche Clinique 2007,1\n373,PROGRAMME HOSPITALIER DE RECHERCHE CLINIQUE 2007,No Description,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n76,SEPTIC SHOCK,DROTRECOGIN ALFA (ACTIVATED),\"Drotrecogin alfa (activated) was initially used in the treatment of septic shock before it was withdrawn from the market. This medication was specifically aimed at managing septic shock, a severe condition, but due to various reasons, it is no longer available for this purpose.\",84\n75,SEPTIC SHOCK,HYDROCORTISONE-PLUS-FLUDROCORTISONE,\"The therapy was evaluated for its effectiveness in treating septic shock, showing a reduction in mortality\",79\n300,SEVERE SEPSIS,DROTRECOGIN ALFA (ACTIVATED),Drotrecogin alfa activated is used in the treatment of severe sepsis and has shown to reduce mortality rates,29\n414,DROTRECOGIN ALFA (ACTIVATED),APROCCHSS TRIAL,Drotrecogin alfa (activated) was one of the treatments tested in the APROCCHSS trial for septic shock,16\n415,DROTRECOGIN ALFA (ACTIVATED),HYDROCORTISONE PLUS FLUDROCORTISONE,The potential interaction between drotrecogin alfa (activated) and hydrocortisone plus fludrocortisone was not assessed due to the withdrawal of Xigris from the market,13\n10,ELI LILLY,DROTRECOGIN ALFA (ACTIVATED),Eli Lilly is the producer of drotrecogin alfa activated,13\n412,DROTRECOGIN ALFA (ACTIVATED),APROCCHSS,The APROCCHSS trial was designed to evaluate drotrecogin alfa (activated) among other therapies for septic shock before its withdrawal,11\n566,XIGRIS,APROCCHSS TRIAL,The trial continued with two parallel groups after Xigris was withdrawn from the market,11\n413,DROTRECOGIN ALFA (ACTIVATED),XIGRIS,\"Drotrecogin alfa (activated), also known as Xigris, is a medication that was available under the brand name Xigris. It was withdrawn from the market in 2011. Xigris served as the commercial form of drotrecogin alfa (activated), indicating that both names refer to the same product. The withdrawal applies universally to the product, regardless of the name it was marketed under.\",9\n563,HYDROCORTISONE-PLUS-FLUDROCORTISONE,APROCCHSS,The APROCCHSS trial evaluated the effectiveness of hydrocortisone-plus-fludrocortisone therapy in septic shock,6\n564,APROCCHSS,FRENCH MINISTRY OF SOCIAL AFFAIRS AND HEALTH,The APROCCHSS trial was funded by the French Ministry of Social Affairs and Health,5\n565,APROCCHSS,PROGRAMME HOSPITALIER DE RECHERCHE CLINIQUE 2007,The program funded the APROCCHSS clinical trial,5\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4-turbo-preview", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}